A Multicenter, Open-Label Safety Study of Natalizumab administered to Subjects with Relapsing Forms of Multiple Sclerosis who participated in STRATA.
Phase of Trial: Phase IV
Latest Information Update: 17 Apr 2018
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Biogen
- 14 Apr 2018 Status changed from recruiting to completed.
- 04 Mar 2015 New trial record